AI assistant
Entrada Therapeutics, Inc. — Director's Dealing 2021
Oct 29, 2021
33674_dirs_2021-10-28_71b47a1b-3afb-45ae-a580-909ac74fd04d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-10-28
Reporting Person: Doshi Dipal (Director, President and CEO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 174460 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.74 | 2029-05-14 | Common Stock (409989) | Direct | |
| Stock Option (Right to Buy) | $2.10 | 2030-12-16 | Common Stock (140362) | Direct | |
| Stock Option (Right to Buy) | $8.47 | 2031-05-20 | Common Stock (312750) | Direct | |
| Stock Option (Right to Buy) | $12.52 | 2031-08-02 | Common Stock (82920) | Direct |
Footnotes
F1: Consists of (i) 156,465 shares of common stock and (ii) 17,995 shares of restricted common stock issued upon early exercise of stock options.
F2: 25% of the shares subject to this option vested and became exercisable on December 31, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3: 25% of the shares subject to this option shall vest and become exercisable on August 12, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4: 25% of the shares subject to this option shall vest and become exercisable on March 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5: 25% of the shares subject to this option shall vest and become exercisable on August 2, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.